Literature DB >> 17420212

Lysostaphin in treatment of neonatal Staphylococcus aureus infection.

Okunola Oluola1, Lingkun Kong, Mindy Fein, Leonard E Weisman.   

Abstract

This study describes lysostaphin's effect against methicillin-sensitive Staphylococcus aureus in suckling rats. Standard techniques determined minimal inhibitory and bactericidal concentrations, pharmacokinetics, and efficacy. The numbers of surviving rats after vancomycin, oxacillin, and lysostaphin treatment were comparable and were different from that of controls (P < 0.00001). Lysostaphin appears effective in the treatment of neonatal S. aureus infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17420212      PMCID： PMC1891369          DOI： 10.1128/AAC.00506-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model.

Authors:  John F Kokai-Kun; Scott M Walsh; Tanya Chanturiya; James J Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit.

Authors:  J J Dajcs; B A Thibodeaux; E B Hume; X Zheng; G D Sloop; R J O'Callaghan
Journal:  Curr Eye Res       Date:  2001-06       Impact factor: 2.424

4.  Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.

Authors:  Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole
Journal:  Pediatrics       Date:  2002-08       Impact factor: 7.124

Review 5.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.

Authors:  Julie A Wu; Caroline Kusuma; James J Mond; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.

Authors:  Brian J Kopp; David E Nix; Edward P Armstrong
Journal:  Ann Pharmacother       Date:  2004-07-20       Impact factor: 3.154

8.  Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit.

Authors:  Rachel L Chapman; Roger G Faix
Journal:  Pediatr Infect Dis J       Date:  2003-01       Impact factor: 2.129

9.  Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.

Authors:  Scott Walsh; Anjali Shah; James Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 10.  Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient.

Authors:  Leonard E Weisman
Journal:  Curr Opin Infect Dis       Date:  2004-06       Impact factor: 4.915
View more
  5 in total

1.  Antistaphylococcal nanocomposite films based on enzyme-nanotube conjugates.

Authors:  Ravindra C Pangule; Sarah J Brooks; Cerasela Zoica Dinu; Shyam Sundhar Bale; Sharon L Salmon; Guangyu Zhu; Dennis W Metzger; Ravi S Kane; Jonathan S Dordick
Journal:  ACS Nano       Date:  2010-07-27       Impact factor: 15.881

2.  Random mutagenesis identifies novel genes involved in the secretion of antimicrobial, cell wall-lytic enzymes by Lactococcus lactis.

Authors:  Yu Pei Tan; Philip M Giffard; Daniel G Barry; Wilhelmina M Huston; Mark S Turner
Journal:  Appl Environ Microbiol       Date:  2008-10-17       Impact factor: 4.792

3.  Evaluation of Topical Lysostaphin as a Novel Treatment for Instrumented Rhesus Macaques (Macaca mulatta) Infected with Methicillin-Resistant Staphylococcus aureus.

Authors:  Christopher E Cheleuitte-Nieves; Leslie L Diaz; Maria Pardos de la Gandara; Alejandra Gonzalez; Winrich A Freiwald; Hermínia M de Lencastre; Alexander Tomasz; Chad W Euler
Journal:  Comp Med       Date:  2020-08-13       Impact factor: 0.982

Review 4.  Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications.

Authors:  Maria do Carmo de Freire Bastos; Bruna Gonçalves Coutinho; Marcus Lívio Varella Coelho
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-19

5.  Fusion of Lysostaphin to an Albumin Binding Domain Prolongs Its Half-Life and Bactericidal Activity in the Systemic Circulation.

Authors:  Alexander V Grishin; Nikita V Shestak; Natalia V Lavrova; Alexander M Lyashchuk; Liubov I Popova; Natalia V Strukova; Maria S Generalova; Anna V Ryazanova; Nikita B Polyakov; Zoya M Galushkina; Lyubov A Soboleva; Irina S Boksha; Anna S Karyagina; Vladimir G Lunin
Journal:  Molecules       Date:  2019-08-09       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.